虚血性心疾患（IHD）治療薬の世界市場レポート 2025年

虚血性心疾患（IHD）治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR4.0％で78億6,000万米ドルに成長します。予測期間の成長は、人口の高齢化動向、個別化医療アプローチ、心血管予防の重視、世界の保健政策とイニシアチブ、国際的な研究協力に起因します。予測期間における主な動向としては、精密医療アプローチへのシフト、新規抗動脈硬化薬への注目、脂質低下療法の進歩、抗炎症薬の統合、抗血栓薬および抗血小板薬の開発などが挙げられます。

肥満と糖尿病の増加率が、今後数年間の虚血性心疾患（IHD）治療薬市場の成長を牽引すると予想されます。糖尿病は高血糖を引き起こす慢性代謝性疾患であり、肥満は健康を害する可能性のある過剰な体脂肪を特徴とする疾患です。IHD治療薬は、高血圧や脂質異常症などの心血管危険因子を管理し、虚血性心疾患の可能性を減らすために、肥満や糖尿病の患者に対して頻繁に処方されています。例えば、英国を拠点に世界の肥満対策に取り組む団体である世界肥満連盟は、2022年に、2030年までに世界で10億人（女性の5人に1人、男性の7人に1人を含む）が肥満を抱えながら生活するようになると報告しました。同様に、2024年6月、英国の国民保健サービス（NHS）は、イングランドでさらに54万9000人が2型糖尿病のリスクがあることを確認し、GPに登録された非糖尿病性高血糖（糖尿病予備軍）の総数は361万5330人となり、2022年の306万5825人から20％近く増加しました。このような肥満と糖尿病の有病率の上昇が、IHD治療薬市場の成長を牽引しています。

心不全の発生率の増加も、虚血性心疾患（IHD）治療薬市場の成長に寄与すると予想される要因の一つです。心不全は、心筋が十分な血液を送り出せなくなる慢性疾患で、しばしば疲労や息切れなどの症状を引き起こします。虚血性心疾患治療薬は、IHDに関連する危険因子や症状を軽減することで、心不全治療に重要な役割を果たしています。これらの薬剤は駆出率が低下し、安静時心拍数が高い心不全患者に特に有効です。例えば、2023年9月にアメリカ心不全学会が発表したデータによると、20歳以上のアメリカ人のうち670万人が心不全であり、この有病率は2030年までに850万人に増加すると予想されています。心不全の罹患率の上昇は、虚血性心疾患（IHD）治療薬市場の成長にとって重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界虚血性心疾患（IHD）治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の虚血性心疾患（IHD）治療薬市場：成長率分析
• 世界の虚血性心疾患（IHD）治療薬市場の実績：規模と成長, 2019-2024
• 世界の虚血性心疾患（IHD）治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界虚血性心疾患（IHD）治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の虚血性心疾患（IHD）治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 脂質異常症治療薬
• カルシウムチャネル遮断薬
• ベータ遮断薬
• アンジオテンシン変換酵素（ACE）阻害剤
• アンジオテンシンII受容体拮抗薬（ARB）
• 血管拡張薬
• 抗血栓剤
• 世界の虚血性心疾患（IHD）治療薬市場疾患クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 狭心症
• 心筋梗塞
• 世界の虚血性心疾患（IHD）治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の虚血性心疾患（IHD）治療薬市場、脂質異常症治療薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• スタチン
• フィブラート
• ナイアシン
• コレステロール吸収阻害剤
• 世界の虚血性心疾患（IHD）治療薬市場カルシウムチャネル遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジヒドロピリジン
• 非ジヒドロピリジン
• 世界の虚血性心疾患（IHD）治療薬市場、ベータ遮断薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心臓選択性ベータ遮断薬
• 非選択的ベータ遮断薬
• 血管拡張性ベータ遮断薬
• 世界の虚血性心疾患（IHD）治療薬市場アンジオテンシン変換酵素（ACE）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エナラプリル
• リシノプリル
• ラミプリル
• 世界の虚血性心疾患（IHD）治療薬市場アンジオテンシンII受容体拮抗薬（ARB）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロサルタン
• バルサルタン
• イルベサルタン
• 世界の虚血性心疾患（IHD）治療薬市場血管拡張薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニトログリセリン
• イソソルビドジニトラート
• ヒドララジン
• 世界の虚血性心疾患（IHD）治療薬市場抗血栓剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗血小板薬
• 抗凝固剤

第7章 地域別・国別分析

• 世界の虚血性心疾患（IHD）治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の虚血性心疾患（IHD）治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 虚血性心疾患（IHD）治療薬市場：競合情勢
• 虚血性心疾患（IHD）治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GSK PLC
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz Inc.
• Sun Pharmaceutical Industries Limited
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Lupin Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 虚血性心疾患（IHD）治療薬市場2029：新たな機会を提供する国
• 虚血性心疾患（IHD）治療薬市場2029：新たな機会を提供するセグメント
• 虚血性心疾患（IHD）治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ischemic heart disease (IHD) drugs refer to medications employed in the management and treatment of a condition characterized by reduced blood flow to the heart muscle, often due to narrowing of the coronary arteries. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

The primary drug classes encompassed by ischemic heart disease (IHD) drugs include anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are pharmacological agents targeting and reducing abnormal lipid levels (such as cholesterol and triglycerides) in the bloodstream to mitigate the risk of cardiovascular disease. These drugs are utilized in the treatment of various conditions, including angina pectoris and myocardial infarction, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The ischemic heart disease (IHD) drugs market research report is one of a series of new reports from The Business Research Company that provides ischemic heart disease (IHD) drugs market statistics, including ischemic heart disease (IHD) drugs industry global market size, regional shares, competitors with a ischemic heart disease (IHD) drugs market share, detailed ischemic heart disease (IHD) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ischemic heart disease (IHD) drugs industry. This ischemic heart disease (IHD) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ischemic heart disease (IHD) drugs market size has grown strongly in recent years. It will grow from $6.36 billion in 2024 to $6.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies.

The ischemic heart disease (IHD) drugs market size is expected to see steady growth in the next few years. It will grow to $7.86 billion in 2029 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs.

The increasing rates of obesity and diabetes are anticipated to drive the growth of the ischemic heart disease (IHD) drugs market in the coming years. Diabetes, a chronic metabolic disorder leading to high blood glucose levels, and obesity, a condition marked by excessive body fat that can harm health, are both key risk factors for cardiovascular issues. IHD drugs are frequently prescribed for individuals with obesity and diabetes to manage cardiovascular risk factors like hypertension and dyslipidemia, thereby reducing the likelihood of ischemic heart disease. For example, the World Obesity Federation, a UK-based organization working to address obesity worldwide, reported in 2022 that by 2030, one billion people globally-including 1 in 5 women and 1 in 7 men-will be living with obesity. Similarly, in June 2024, the National Health Service (NHS) in the UK identified an additional 549,000 people in England at risk of type 2 diabetes, bringing the total number of individuals with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, up nearly 20% from 3,065,825 in 2022. This rising prevalence of obesity and diabetes is thus driving growth in the IHD drugs market.

The increasing incidence of heart failure is another factor expected to contribute to the growth of the ischemic heart disease (IHD) drug market. Heart failure, a chronic condition where the heart muscle cannot pump enough blood, often leads to symptoms such as fatigue and shortness of breath. Ischemic heart disease drugs play a crucial role in treating heart failure by reducing risk factors and symptoms associated with IHD. These medications can be particularly beneficial for heart failure patients with reduced ejection fractions and high resting heart rates. For instance, data from the Heart Failure Society of America in September 2023 indicates that 6.7 million Americans over 20 years of age have heart failure, and this prevalence is expected to increase to 8.5 million Americans by 2030. The rising incidence of heart failure is a key driver for the growth of the ischemic heart disease (IHD) drug market.

Leading companies in the ischemic heart disease (IHD) drugs market are increasingly focusing on developing innovative myosin inhibitors to strengthen their competitive position. Cardiac myosin inhibitors work by reducing myosin activity in the heart muscle, thereby lowering contraction force. This approach is particularly useful for treating conditions like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening hinders heart function. For example, in April 2022, Bristol Myers Squibb, a U.S.-based pharmaceutical company, introduced Camzyos (mavacamten), the first cardiac myosin inhibitor approved to treat adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive HCM, aiming to enhance functional capacity and relieve symptoms. Camzyos acts as a selective, allosteric, and reversible inhibitor of cardiac myosin, reducing hypercontractility, left ventricular hypertrophy, and cardiac filling pressures, which helps alleviate dynamic left ventricular outflow tract (LVOT) obstruction.

In March 2024, Denmark-based pharmaceutical company Novo Nordisk acquired Cardior Pharmaceuticals for an undisclosed sum. This acquisition marks a key step in Novo Nordisk's strategy to build and expand its portfolio in cardiovascular disease, a leading cause of death globally. Cardior Pharmaceuticals, based in Germany, specializes in manufacturing cardiovascular drugs for ischemic heart disease (IHD).

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ischemic heart disease (IHD) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ischemic heart disease (IHD) drugs market consists of sales of antiarrhythmic drugs, anticoagulants, anti-anginal medications, nitroglycerin and nitrates, statins, and antiplatelet agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ischemic Heart Disease (IHD) Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ischemic heart disease (ihd) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ischemic heart disease (ihd) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ischemic heart disease (ihd) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Anti-Dyslipidemic Drugs; Calcium Channel Blockers; Beta-Blockers; Angiotensin-converting enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Vasodilators; Antithrombotic Agents
• 2) By Disease Class: Angina Pectoris; Myocardial Infarction
• 3) By End User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Anti-Dyslipidemic Drugs: Statins; Fibrates; Niacin; Cholesterol Absorption Inhibitors
• 2) By Calcium Channel Blockers: Dihydropyridines; Non-Dihydropyridines
• 3) By Beta-Blockers: Cardioselective Beta-Blockers; Non-Selective Beta-Blockers; Vasodilating Beta-Blockers
• 4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril; Lisinopril; Ramipril
• 5) By Angiotensin II Receptor Blockers (ARBs): Losartan; Valsartan; Irbesartan
• 6) By Vasodilators: Nitroglycerin; Isosorbide Dinitrate; Hydralazine
• 7) By Antithrombotic Agents: Antiplatelet Drugs; Anticoagulants
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ischemic Heart Disease (IHD) Drugs Market Characteristics

3. Ischemic Heart Disease (IHD) Drugs Market Trends And Strategies

4. Ischemic Heart Disease (IHD) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Ischemic Heart Disease (IHD) Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ischemic Heart Disease (IHD) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ischemic Heart Disease (IHD) Drugs Market Growth Rate Analysis
• 5.4. Global Ischemic Heart Disease (IHD) Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ischemic Heart Disease (IHD) Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ischemic Heart Disease (IHD) Drugs Total Addressable Market (TAM)

6. Ischemic Heart Disease (IHD) Drugs Market Segmentation

• 6.1. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Dyslipidemic Drugs
• Calcium Channel Blockers
• Beta-Blockers
• Angiotensin-converting enzyme (ACE) Inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Vasodilators
• Antithrombotic Agents
• 6.2. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angina Pectoris
• Myocardial Infarction
• 6.3. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Statins
• Fibrates
• Niacin
• Cholesterol Absorption Inhibitors
• 6.5. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dihydropyridines
• Non-Dihydropyridines
• 6.6. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardioselective Beta-Blockers
• Non-Selective Beta-Blockers
• Vasodilating Beta-Blockers
• 6.7. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enalapril
• Lisinopril
• Ramipril
• 6.8. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Losartan
• Valsartan
• Irbesartan
• 6.9. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitroglycerin
• Isosorbide Dinitrate
• Hydralazine
• 6.10. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiplatelet Drugs
• Anticoagulants

7. Ischemic Heart Disease (IHD) Drugs Market Regional And Country Analysis

• 7.1. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market

• 8.1. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ischemic Heart Disease (IHD) Drugs Market

• 9.1. China Ischemic Heart Disease (IHD) Drugs Market Overview
• 9.2. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ischemic Heart Disease (IHD) Drugs Market

• 10.1. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ischemic Heart Disease (IHD) Drugs Market

• 11.1. Japan Ischemic Heart Disease (IHD) Drugs Market Overview
• 11.2. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ischemic Heart Disease (IHD) Drugs Market

• 12.1. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ischemic Heart Disease (IHD) Drugs Market

• 13.1. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ischemic Heart Disease (IHD) Drugs Market

• 14.1. South Korea Ischemic Heart Disease (IHD) Drugs Market Overview
• 14.2. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ischemic Heart Disease (IHD) Drugs Market

• 15.1. Western Europe Ischemic Heart Disease (IHD) Drugs Market Overview
• 15.2. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ischemic Heart Disease (IHD) Drugs Market

• 16.1. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ischemic Heart Disease (IHD) Drugs Market

• 17.1. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ischemic Heart Disease (IHD) Drugs Market

• 18.1. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ischemic Heart Disease (IHD) Drugs Market

• 19.1. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ischemic Heart Disease (IHD) Drugs Market

• 20.1. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market

• 21.1. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market Overview
• 21.2. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ischemic Heart Disease (IHD) Drugs Market

• 22.1. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ischemic Heart Disease (IHD) Drugs Market

• 23.1. North America Ischemic Heart Disease (IHD) Drugs Market Overview
• 23.2. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ischemic Heart Disease (IHD) Drugs Market

• 24.1. USA Ischemic Heart Disease (IHD) Drugs Market Overview
• 24.2. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ischemic Heart Disease (IHD) Drugs Market

• 25.1. Canada Ischemic Heart Disease (IHD) Drugs Market Overview
• 25.2. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ischemic Heart Disease (IHD) Drugs Market

• 26.1. South America Ischemic Heart Disease (IHD) Drugs Market Overview
• 26.2. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ischemic Heart Disease (IHD) Drugs Market

• 27.1. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ischemic Heart Disease (IHD) Drugs Market

• 28.1. Middle East Ischemic Heart Disease (IHD) Drugs Market Overview
• 28.2. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ischemic Heart Disease (IHD) Drugs Market

• 29.1. Africa Ischemic Heart Disease (IHD) Drugs Market Overview
• 29.2. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape And Company Profiles

• 30.1. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape
• 30.2. Ischemic Heart Disease (IHD) Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Ischemic Heart Disease (IHD) Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. GSK PLC
• 31.6. Eli Lilly and Company
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Viatris Inc.
• 31.9. Baxter International Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Sandoz Inc.
• 31.12. Sun Pharmaceutical Industries Limited
• 31.13. Dr. Reddy's Laboratories Ltd.
• 31.14. Cipla Limited
• 31.15. Lupin Limited

32. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market

34. Recent Developments In The Ischemic Heart Disease (IHD) Drugs Market

35. Ischemic Heart Disease (IHD) Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer